NeoGenomics is projected to report third-quarter revenue of $182.5 million and a loss per share of $0.01, with its current $16.85 stock price trading significantly below the $21.20 analyst consensus target.
The primary focus for investors this quarter is the volume growth of the RaDaR minimal residual disease assay and its overall contribution to Clinical Services revenue.
Markets are looking for evidence that recent laboratory optimizations are successfully driving gross margin improvements despite a competitive pricing environment.
This report is seen as a key indicator of the company’s progress toward sustained positive free cash flow and operational stability in the oncology testing landscape.